Japanese guidelines for adult asthma 2017☆

Abstract

Adult bronchial asthma is characterized by chronic airway inflammation, and presents clinically with variable airway narrowing (wheezes and dyspnea) and cough. Long-standing asthma induces airway remodeling, leading to intractable asthma. The number of patients with asthma has increased; however, the number of patients who die of asthma has decreased (1.2 per 100,000 patients in 2015). The goal of asthma treatment is to enable patients with asthma to attain normal pulmonary function and lead a normal life, without any symptoms. A good relationship between physicians and patients is indispensable for appropriate treatment. Long-term management by therapeutic agents and elimination of the causes and risk factors of asthma are fundamental to its treatment. Four steps in pharmacotherapy differentiate between mild and intensive treatments; each step includes an appropriate daily dose of an inhaled corticosteroid, varying from low to high levels. Long-acting β2-agonists, leukotriene receptor antagonists, sustained-release theophylline, and long-acting muscarinic antagonist are recommended as add-on drugs, while anti-immunoglobulin E antibody and oral steroids are considered for the most severe and persistent asthma related to allergic reactions. Bronchial thermoplasty has recently been developed for severe, persistent asthma, but its long-term efficacy is not known. Inhaled β2-agonists, aminophylline, corticosteroids, adrenaline, oxygen therapy, and other approaches are used as needed during acute exacerbations, by choosing treatment steps for asthma in accordance with the severity of exacerbations. Allergic rhinitis, eosinophilic chronic rhinosinusitis, eosinophilic otitis, chronic obstructive pulmonary disease, aspirin-induced asthma, and pregnancy are also important issues that need to be considered in asthma therapy.

Abstract
Full Text
Images
References

 
 

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma RT @Aller_MD: Stallergenes Greer Announces Submission of New Drug Application for Pediatric Use of ACTAIR® in Japan https://t.co/cZDUfBE069
5hreplyretweetfavorite
Interasma RT @Aller_MD: FARE announces recipients of 2017 Investigator in Food Allergy Awards https://t.co/voT8AmGFmm
5hreplyretweetfavorite
Interasma RT @Aller_MD: “Strategies to Alter the Natural History of Childhood #Asthmahttps://t.co/4LFtauTtNw https://t.co/H8DdZsebZ2
5hreplyretweetfavorite
Interasma RT @Aller_MD: New Peanut Introduction Guidance https://t.co/ch5ltEOjgx https://t.co/LaGsIfjoMi
5hreplyretweetfavorite
Interasma Top story: European Commission considering leap into open-access publishing | S… https://t.co/KNBfbUmo3n, see more https://t.co/CpGiFuOOYd
11hreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

InterAsma